加用尤瑞克林对急性分水岭脑梗死患者神经功能及生活质量恢复的影响

目的研究尤瑞克林治疗急性分水岭脑梗死的临床疗效及对神经功能和生活质量的影响。方法选取我院2015年8月至2016年6月期间收治的急性分水岭脑梗死患者106例,采用随机数字法将其分为对照组和观察组,每组53例。对照组患者接受抗凝,调脂,控制血糖、血压等常规治疗,在此基础上,观察组患者静脉滴注尤瑞克林治疗,所有患者均连续治疗3周。比较两组患者的临床疗效,治疗前后评价两组患者的神经功能、生活质量及缺血区脑血流灌注情况,并观察不良反应。结果观察组的治疗总有效率(88.68%)明显高于对照组(71.70%)(χ~2=4.81,P=0.02);治疗后,观察组的美国国立卫生研究院卒中量表(NIHSS)评分明显低于对照组(t=5.68,P<0.01),日常生活能力量表(BI)评分明显高于对照组(t=6.43,P<0.01),观察组的局部脑血容量(r CBV)水平明显高于对照组(t=4.72,P<0.01),局部脑血流量(r CBF)、局部达峰时间(r TTP)、局部平均通过时间(r MTT)水平明显低于对照组(P<0.01);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论尤瑞克林治疗急性分水岭脑梗死具有非常显著的临床疗效,可以快速恢复梗死区域血流灌注,有效改善患者神经功能及生活质量,且治疗安全性高,值得在临床推广。

Effect of urinary kallidinogenase combined with conventional therapy on neurological function and quality of life in patients with acute cerebral watershed infarction(CWSI)

Objective To study the clinical effect of urinary kallidinogenase in the treatment of patients with acute cerebral watershed infarction (CWSI) and its influence on neurological function and quality of life in these patients.Methods Totally 106 patients with acute CWSI in our hospital from August 2015 to June 2016 were selected and randomly divided into control group and observation group,53 cases in each group.Control group received anticoagulation,lipid regulation,blood glucose and blood pressure control and other conventional treatment;observation group were treated with intravenous drip of urinary kallidinogenase on the basis of control group,all patients were treated for 3 consecutive weeks.The clinical curative effect of the two groups were compared,and the neurological function,quality of life and the brain perfusion of the ischemic area were evaluated.The adverse reactions of the two groups were observed.Results The total effective rate in observation group (88.68％) was significantly higher than the control group (71.70％) (x2 =4.81,P =0.02).After treatment,the NIHSS score and the levels of rCBF,rTTP and rMTT of observation group were significantly lower than those of control group (P ＜0.01),BI score and the rCBV were significantly higher than those of control group (P ＜ 0.01).There was no significant difference in the adverse reaction rate between the two groups (P ＞ 0.05).Conclusion Urinary kallidinogenase has significant clinical efficacy and high safety in the treatment of acute CWSI infarction,which can rapidly restore the regional blood perfusion,improve neurological function and quality of life,it is worthy of clinical promotion.